ClinicalTrials.gg
RecruitingNCT06567782AZUR-4Updated May 22, 2026

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

A Phase 2 interventional study of Dostarlimab and CAPEOX in Neoplasms, Colon, sponsored by GlaxoSmithKline. Recruiting at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Colonic Neoplasms with a site in Belgium — 14 open to participants now, 22 under way, 7 of them phase 3. Colonic Neoplasms · Belgium.

Planned enrollment
32nd of 51
120 · median 283
Started
2025
with 3 others
Phase 2
11 of 64
3 open now
Primary completion
2026-11
later than 8 of 21 live
Registered
56th of 64
by date
Lead sponsor
3 of 64
GlaxoSmithKline

Among the 64 studies in Colonic Neoplasms with a site in Belgium, this one is the 32nd largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 8 of the 21 other live ones, and was the 56th registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

14 of the 64 studies in Colonic Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Colonic Neoplasms with a site in Belgium, or all of them as a file.
02

Study summary

The main goal of this study is to test a new treatment approach for colon cancer. The treatment involves dostarlimab along with a specific type of chemotherapy called CAPEOX (short for "capecitabine + oxaliplatin") to check if using these two together works better than using just CAPEOX by itself. This treatment is given before any surgery takes place; a method referred to as "neoadjuvant therapy." . The aim is to see if this new approach can show early signs of effectiveness in treating participants with a specific type of colon cancer known as mismatch repair proficient/ microsatellite stable (MMRp/MSS), where the cells have normal repair systems and stable DNA sequences. This study will also look at specific signs in the blood and tumor to see if they can help predict how well the treatment is working. This could help better understand how dostarlimab contributes to the response of the disease to treatment.

03

Conditions studied

  • Neoplasms, Colon

Browse trials for

Keywords

  • Colon cancer
  • MMRp
  • MSS
  • Dostarlimab
  • CAPEOX
  • Neoadjuvant
  • GSK4057190A
  • TSR-042
  • Chemotherapy
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has untreated confirmed colon adenocarcinoma
  • Has resectable colon adenocarcinoma defined as clinically T4N0 or Stage III
  • Has a tumor demonstrating the presence of either-

    1. MMR status: MMR status must be assessed by Immunohistochemistry (IHC) for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where all proteins are present indicates MMRp; MMR status may be determined local laboratory; or
    2. MSS or Microsatellite Instability-L (MSI-L) phenotype as determined by polymerase chain reaction (PCR) or by tissue next generation sequencing (NGS), determined by local laboratory
  • Provides fresh tumor tissue obtained during either the pre-screening or screening period via colonoscopy performed per procedure manual. Tissue is required
  • Is willing to use adequate male and/or female participants
  • Has an - Performance status (ECOG-PS) of 0 or 1
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has distant disease
  • Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of colon cancer
  • Has, in the investigator's opinion, a tumor that is not amenable to surgery or has any other to surgery
  • Has experienced any of the following with prior immunotherapy: any imAE ≥ Grade 3, immune-mediated severe neurologic events of any-grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade [Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), or Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome], or myocarditis of any grade. Non- laboratory abnormalities are not exclusionary
  • Has any history of interstitial lung disease or immune-related pneumonitis
  • Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the study results, interfere with their participation for the full duration of the study intervention, or indicate it is not in the best interest of the participant to participate, in the opinion of the investigator
  • Is considered, in investigator's opinion, a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active infection requiring systemic therapy
  • Has received treatment with an agent within [4 weeks] of the first dose of study intervention
  • Is pregnant or breastfeeding
  • Has a history of severe allergic and/or anaphylactic reactions to chimeric, human, or humanized antibodies, fusion proteins, or known allergies to dostarlimab, or its , or any components of CAPEOX
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Dostarlimab plus CAPEOX

    Participants will receive dostarlimab plus CAPEOX (chemotherapy).

    Biological: Dostarlimab · Drug: CAPEOX

  • Active comparator
    CAPEOX

    Participants will receive CAPEOX (chemotherapy).

    Drug: CAPEOX

Interventions

  • BiologicalDostarlimab

    Dostarlimab will be administered.

    Also known as: GSK4057190A, TSR-042

  • DrugCAPEOX

    Drug page: Xelox

    CAPEOX chemotherapy consisting of capecitabine and oxaliplatin will be administered.

06

What researchers measure

Primary outcomes

  1. Major pathological response (mPR) rate

    mPR rate is defined as the proportion of participants with ≤10% residual viable tumor (RVT) value in the surgical resection sample as determined by local assessment.

    Time frame: Up to approximately 18 weeks

  2. Number of participants with adverse events (AEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs), and AEs leading to death or discontinuation of study intervention

    Time frame: Up to approximately 105 weeks

Secondary outcomes

  1. Percentage of participants for whom primary tumour resection is not excluded

    Time frame: Up to approximately 18 weeks

  2. Complete pathologic response (cPR) rate

    cPR rate is defined as the proportion of participants with 0% RVT value in the surgical resection sample as determined by local assessment.

    Time frame: Up to approximately 18 weeks

  3. Major pathological response excluding cPR rate

    mPR rate is defined as the proportion of participants with ≤10% RVT value in the surgical resection sample as determined by local assessment. cPR rate is defined as the proportion of participants with 0% RVT value in the surgical resection sample as determined by local assessment.

    Time frame: Up to approximately 18 weeks

  4. Partial pathologic response rate

    Partial pathologic response rate is defined as the proportion of participants with \>10% and ≤50% RVT value in the surgical resection sample as determined by local assessment.

    Time frame: Up to approximately 18 weeks

  5. Negligible pathologic response rate

    Negligible pathologic response rate is defined as the proportion of participants with \>50% RVT value in the surgical resection sample as determined by local assessment.

    Time frame: Up to approximately 18 weeks

07

Study locations

32 of 33 sites recruiting
  • GSK Investigational Site
    Aalst, 9300, Belgium
    Recruiting
  • GSK Investigational Site
    Bonheiden, 2820, Belgium
    Recruiting
  • GSK Investigational Site
    Brussels, 1070, Belgium
    Recruiting
  • GSK Investigational Site
    Brussels, 1200, Belgium
    Recruiting
  • GSK Investigational Site
    Ghent, 9000, Belgium
    Recruiting
  • GSK Investigational Site
    Leuven, 3000, Belgium
    Recruiting
  • GSK Investigational Site
    Liège, 4000, Belgium
    Recruiting
  • GSK Investigational Site
    Liège, 4000, Belgium
    Recruiting
  • GSK Investigational Site
    Ostend, 8400, Belgium
    Recruiting
  • GSK Investigational Site
    Roeselare, 8800, Belgium
    Recruiting
  • GSK Investigational Site
    Turnhout, 2300, Belgium
    Recruiting
  • GSK Investigational Site
    Milan, 20162, Italy
    Recruiting
  • GSK Investigational Site
    Roma, 00168, Italy
    Recruiting
  • GSK Investigational Site
    Udine, 33100, Italy
    Recruiting
  • GSK Investigational Site
    Osaka, 565-0871, Japan
    Recruiting
  • GSK Investigational Site
    Osaka, 5731191, Japan
    Recruiting
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • GSK Investigational Site
    Tokyo, 135-8550, Japan
    Recruiting
  • GSK Investigational Site
    Barcelona, 8025, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 8035, Spain
    Recruiting
  • GSK Investigational Site
    Barcelona, 8036, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28007, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28034, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28041, Spain
    Recruiting
  • GSK Investigational Site
    Madrid, 28222, Spain
    Recruiting
  • GSK Investigational Site
    Oviedo, 33011, Spain
    Recruiting
  • GSK Investigational Site
    Valencia, 46010, Spain
    Recruiting
  • GSK Investigational Site
    Bern, 3010, Switzerland
    Recruiting
  • GSK Investigational Site
    Geneva, 1205, Switzerland
    Recruiting
  • GSK Investigational Site
    Glasgow, G12 0YN, United Kingdom
    Recruiting
  • GSK Investigational Site
    Leeds West Yorkshire, LS9 7TF, United Kingdom
    Recruiting
  • GSK Investigational Site
    London, NW1 2PG, United Kingdom
    Recruiting
  • GSK Investigational Site
    Sutton, SM2 5PT, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2026, 21 months after the start.

Of 136 phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2024
First posted
Aug 23, 2024
StartActual
Feb 18, 2025
Primary completionEst.
Nov 23, 2026
CompletionEst.
Oct 26, 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06567782
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 23, 2024
Start date
Feb 18, 2025
Primary completion
Nov 23, 2026 (estimated)
Completion
Oct 26, 2028 (estimated)
Last update
May 22, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion